Considerations for the Integration of Cannabidiol into the Neurologic Disorder Therapeutic Landscape: Spotlight on Epilepsy
PROGRAM CHAIR
Elizabeth A. Thiele, MD, PhD
Director, Pediatric Epilepsy Program
Massachusetts General Hospital
Professor of Neurology
Harvard Medical School
Boston, MA
FACULTY PRESENTER
M. Scott Perry, MD
Head of Neurosciences
Jane and John Justin Institute for Mind Health at Cook Children’s Medical Center
Fort Worth, TX
PROGRAM OVERVIEW
This educational program will aim to discuss cannabidiol use for medical disorders, specifically epilepsy. Â The content will compare cannabidiol from other cannabis-related products, illustrate the mechanisms of action of cannabidiol for epilepsy, and review current clinical data in this area, and discuss the importance of shared decision making in clinical practice, including education on the efficacy and safety profiles of cannabidiol to address misconceptions with patients and caregivers.
TARGET AUDIENCE
This activity is designed to meet the educational needs of neurologists and neurology advanced practice providers (APPs) involved in the management of patients with neurological disorders, such as epilepsy, for whom cannabidiol may be a valid therapeutic option.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the differentiating factors of cannabidiol from other cannabis products and the FDA-approved cannabidiol from over-the-counter (OTC) cannabidiol products
- Evaluate the mechanisms of action (MoA) of cannabidiol in epilepsy and emerging neurologic disorders of interest
- Assess the available and ongoing clinical data which will inform the benefit and risk profile of cannabidiol in epilepsy and emerging neurologic disorders and the data gaps in individualized cannabidiol dosing
- Apply shared decision making (SDM) skills, including education on the efficacy and safety of cannabidiol, to address its inaccurate misconceptions with patients and caregivers
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Elizabeth A. Thiele, MD | Consulting Fee: Jazz Pharmaceuticals, UCB, LivaNova, Biocodex, Stoke Therapeutics, Nobelpharma Contracted Research: Jazz Pharmaceuticals, UCB, Biocodex, Pyros Pharmaceuticals, Takeda |
| M. Scott Perry, MD | Contracted research: Zogenix/UCB, Takeda, Neurocrine, Encoded, Stoke (all funds paid to Cook Children’s) Consulting Fee: Marinus, Stoke Therapeutics, UCB, Neurelis, Cadence, Azurity Pharmaceuticals, Jazz Pharmaceuticals, Biocodex Ownership Interest: Praxis Precision Medicine, Longboard Pharmaceuticals, Rapport Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, has received royalties from Wolters Kluwer (Up ToDate author royalties).
- Sarah Milano, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation and Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: October 17, 2024
EXPIRATION DATE: October 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM FACULTY
M. Scott Perry, MD
Head of Neurosciences
Jane and John Justin Institute for Mind Health at Cook Children’s Medical Center
Fort Worth, TX
PROGRAM OVERVIEW
This educational program will address cannabidiol use for medical disorders, specifically epilepsy. In this podcast, we discuss cannabidiol versus other cannabis-related products, illustrate the mechanisms of action of cannabidiol for epilepsy, and review general approaches for use of CBD in practice.
TARGET AUDIENCE
This activity is designed to meet the educational needs of neurologists and neurology advanced practice providers involved in the management of patients with neurological disorders, such as epilepsy, for whom cannabidiol may be a valid therapeutic option.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the differentiating factors of cannabidiol from other cannabis products and the FDA-approved cannabidiol from OTC cannabidiol products
- Evaluate the mechanism of action of cannabidiol in epilepsy and emerging neurologic disorders of interest
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| M. Scott Perry, MD | Contracted research: Zogenix/UCB, Takeda, Neurocrine Biosciences, Encoded Therapeutics, Stoke Therapeutics (all funds paid to Cook Children’s) Consulting Fee: Marinus, Stoke Therapeutics, UCB, Neurelis, Cadence, Azurity Pharmaceuticals, Jazz Pharmaceuticals, Biocodex Ownership Interest: Praxis Precision Medicine, Longboard Pharmaceuticals, Rapport Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, has received royalties from Wolters Kluwer (UpToDate author royalties).
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation and Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: October 17, 2024
EXPIRATION DATE: October 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM FACULTY
M. Scott Perry, MD
Head of Neurosciences
Jane and John Justin Institute for Mind Health at Cook Children’s Medical Center
Fort Worth, TX
PROGRAM OVERVIEW
This educational program will address cannabidiol use for medical disorders, specifically epilepsy. In this podcast, we review current clinical data on CBD in epilepsy and discuss the importance of shared decision making and multidisciplinary care. Through this we hope to help close the knowledge gaps of both clinicians and patients who are considering therapeutic CBD use for their patients with epilepsy.
TARGET AUDIENCE
This activity is designed to meet the educational needs of neurologists and neurology advanced practice providers involved in the management of patients with neurological disorders, such as epilepsy, for whom cannabidiol may be a valid therapeutic option.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess available and ongoing clinical data, which will inform the benefit and risk profile of cannabidiol in epilepsy, emerging neurologic disorders, and the data gaps in individualized cannabidiol dosing
- Apply shared decision-making (SDM) skills, including education on the efficacy and safety of cannabidiol, to address its inaccurate misconceptions with patients and caregivers
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| M. Scott Perry, MD | Contracted research: Zogenix/UCB, Takeda, Neurocrine Biosciences, Encoded Therapeutics, Stoke Therapeutics (all funds paid to Cook Children’s) Consulting Fee: Marinus, Stoke Therapeutics, UCB, Neurelis, Cadence, Azurity Pharmaceuticals, Jazz Pharmaceuticals, Biocodex Ownership Interest: Praxis Precision Medicine, Longboard Pharmaceuticals, Rapport Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, has received royalties from Wolters Kluwer (UpToDate author royalties).
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation and Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: October 17, 2024
EXPIRATION DATE: October 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
